Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity

被引:166
作者
Feder, R [1 ]
Dagan, A [1 ]
Mor, A [1 ]
机构
[1] Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Lab Antimicrobial Peptides Invest, IL-91904 Jerusalem, Israel
关键词
D O I
10.1074/jbc.275.6.4230
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To understand how peptide organization in aqueous solution might affect the activity of antimicrobial peptides, the potency of various dermaseptin S4 analogs was assessed against human red blood cells (RBC), protozoa, and several Gram-negative bacteria. Dermaseptin 54 had weak antibacterial activity but potent hemolytic or antiprotozoan effects. K4K20-S4 was 2-3 fold more potent against protozoa and RBC, yet K4K20-S4 was more potent by 2 orders of magnitude against bacteria. K-4-S4 had similar behavior as K4K20-S4, but K-20-S4 and analogous negative charge substitutions were as active as dermaseptin 54 or had reduced activity. Binding experiments suggested that potency enhancement was not the result of increased affinity to target cells. In contrast, potency correlated well with aggregation properties. Fluorescence studies indicated that K-20-S4 and all negative charge substitutions were as aggregated as dermaseptin S4, whereas K-4-S4 and K4K20-S4 were clearly less aggregated. Overall, the data indicated that N-terminal domain interaction between dermaseptin 54 monomers is responsible for the peptide's oligomerization in solution and, hence, for its limited spectrum of action. Moreover, bell-shaped dose-response profiles obtained with bacteria but not with protozoa or RBC implied that aggregation can have dramatic consequences on antibacterial activity. Based on these results, we tested the feasibility of selectivity reversal in the activity of dermaseptin 54, Tampering with the composition of the hydrophobic domains by reducing hydrophobicity or by increasing the net positive charge affected dramatically the peptide's activity and resulted in various analogs that displayed potent antibacterial activity but reduced hemolytic activity. Among these, maximal antibacterial activity was displayed by a 15-mer version that was more potent by 2 orders of magnitude compared with native dermaseptin 54, These results emphasize the notion that peptide-based antibiotics represent a highly modular synthetic antimicrobial system and provide indications of how the peptide's physico-chemical properties affect potency and selectivity.
引用
收藏
页码:4230 / 4238
页数:9
相关论文
共 23 条
[1]   STRUCTURE-FUNCTION STUDIES OF AMPHIPHILIC ANTIBACTERIAL PEPTIDES [J].
BESSALLE, R ;
GOREA, A ;
SHALIT, I ;
METZGER, JW ;
DASS, C ;
DESIDERIO, DM ;
FRIDKIN, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (09) :1203-1209
[2]   DESIGN OF MODEL AMPHIPATHIC PEPTIDES HAVING POTENT ANTIMICROBIAL ACTIVITIES [J].
BLONDELLE, SE ;
HOUGHTEN, RA .
BIOCHEMISTRY, 1992, 31 (50) :12688-12694
[3]   PEPTIDE ANTIBIOTICS AND THEIR ROLE IN INNATE IMMUNITY [J].
BOMAN, HG .
ANNUAL REVIEW OF IMMUNOLOGY, 1995, 13 :61-92
[4]   Inhibitory action of a truncated derivative of the amphibian skin peptide dermaseptin s3 on Saccharomyces cerevisiae [J].
Coote, PJ ;
Holyoak, CD ;
Bracey, D ;
Ferdinando, DP ;
Pearce, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2160-2170
[5]   Fungicidal and binding properties of the natural peptides cecropin B and dermaseptin [J].
De Lucca, AJ ;
Bland, JM ;
Jacks, TJ ;
Grimm, C ;
Walsh, TJ .
MEDICAL MYCOLOGY, 1998, 36 (05) :291-298
[6]   MECHANISMS FOR THE MODULATION OF MEMBRANE BILAYER PROPERTIES BY AMPHIPATHIC HELICAL PEPTIDES [J].
EPAND, RM ;
SHAI, YC ;
SEGREST, JP ;
ANANTHARAMAIAH, GM .
BIOPOLYMERS, 1995, 37 (05) :319-338
[7]  
FROHLICH DR, 1991, INT J PEPT PROT RES, V37, P2
[8]   Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic Plasmodium falciparium and the underlying molecular basis [J].
Ghosh, JK ;
Shaool, D ;
Guillaud, P ;
Ciceron, L ;
Mazier, D ;
Kustanovich, I ;
Shai, Y ;
Mor, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (50) :31609-31616
[9]   Peptide antibiotics [J].
Hancock, REW .
LANCET, 1997, 349 (9049) :418-422
[10]  
HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414